Shares of IOBT stock opened at $1.07 on Tuesday. IO Biotech has a 12-month low of $0.66 and a 12-month high of $1.79. The business’s 50 day moving average is $0.97 and its two-hundred day moving ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

IO Biotech (NASDAQ:IOBT – Get Free Report) is projected to release its earnings data on Tuesday, March 4th. Analysts expect IO Biotech to post earnings of ($0.39) per share for the quarter.

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. IO Biotech ...

IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing fro ...

IO Biotech’s proprietary T-win ® platform is designed to selectively modulate TGF-β activity rather than fully inhibit it, targeting both tumor cells and key immune-suppressive cells within ...

Fast Company recognizes 609 organizations across 58 sectors and regions. IO Biotech has been recognized for its potentially game-changing approach to immune-mod • Findings support the ...

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq ...